MRNA Expands mRNA Pipeline
Moderna highlights expansion of its mRNA platform across oncology, multiple sclerosis and autoimmune diseases
MRNA Moderna Highlights Next Wave Of mRNA Pipeline At Science Day · Moderna highlighted expansion of its mRNA platform across oncology, multiple sclerosis and autoimmune diseases · The company introduced its in vivo CAR-T program for autoimmune diseases and highlighted progress in its T-cell engager programs · Phase 1 Part B data for mRNA-1195 in EBV-associated multiple sclerosis is expected in 2H 2026 · Moderna said Horizon 3 programs could begin first-in-human studies by the end of 2027